Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Issue 7 (3rd July 2018)

• Record Type: Journal Article
• Authors: Gleeson, Mary; Peckitt, Clare; Cunningham, David; Gibb, Adam; Hawkes, Eliza A.; Back, Morgan; Yasar, Binnaz; Foley, Kate; Lee, Rebecca; Dash, Joanna; Johnson, Hannah; O'Hara, Catherine; Wotherspoon, Andrew; Attygalle, Ayoma; Menasce, Lia; Shenjere, Patrick; Potter, Mike; Ethell, Mark E.; Dearden, Claire; Radford, John; Chau, Ian; Linton, Kim
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 7(2018)
• Page Start: 1586
• Page End: 1595
• Publication Date: 2018-07-03
• Subjects: Peripheral T-cell lymphoma -- chemotherapy -- hematopoietic progenitor cell transplant; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1393671
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) ( n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) ( n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative ( n = 23, 14.7%), ALCL ALK positive ( n = 16, 10.3%), and other ( n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS ( p = .001) and OS ( p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.